Bristol-Myers Squibb Profit Margin 2006-2018 | BMY

Current and historical gross margin, operating margin and net profit margin for Bristol-Myers Squibb (BMY) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Bristol-Myers Squibb net profit margin as of December 31, 2018 is 21.95%.
Bristol-Myers Squibb Annual Profit Margins
Bristol-Myers Squibb Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $74.378B $22.561B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $368.953B 16.73
Pfizer (PFE) United States $234.424B 13.13
Merck (MRK) United States $197.334B 16.86
Novartis AG (NVS) Switzerland $176.507B 15.01
Eli Lilly (LLY) United States $119.326B 20.72
Novo Nordisk (NVO) Denmark $118.242B 19.13
AbbVie (ABBV) United States $114.422B 9.81
Sanofi (SNY) France $103.609B 12.79
GlaxoSmithKline (GSK) United Kingdom $98.852B 12.98
AstraZeneca (AZN) United Kingdom $98.276B 11.21